October 9, 2019
Shionogi: cefiderocol met primary endpoint in phase III study in adults with nosocomial pneumonia
Shionogi has reported positive Results from Cefiderocol Phase III study in adults with nosocomial pneumonia caused by gram-negative pathogens, as cefiderocol met primary endpoint of non-inferiority in 14-day all-cause mortality compared to high-dose meropenem.